Matching articles for "Copaxone"
Issue 1722 · February 17, 2025 Free
In Brief: Anaphylaxis with Glatiramer Acetate

The FDA has required a new boxed warning in the label of the subcutaneously injected immunomodulatory drug glatiramer acetate ( Copaxone , Glatopa , and generics) about a risk of anaphylaxis. Glatiramer has…

Med Lett Drugs Ther. 2025 Feb 17; 67(1722):32 doi:10.58347/tml.2025.1722e
The FDA has required a new boxed warning in the label of the subcutaneously injected immunomodulatory drug glatiramer acetate ( Copaxone , Glatopa , and generics) about a risk of anaphylaxis. Glatiramer has been used for years to treat relapsing forms of multiple sclerosis (MS).
Issue 1671 · March 6, 2023
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis

The FDA has approved the recombinant chimeric anti-CD20 antibody ublituximab-xiiy ( Briumvi – TG Therapeutics) for IV treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):36-8 doi:10.58347/tml.2023.1671c
The FDA has approved the recombinant chimeric anti-CD20 antibody ublituximab-xiiy ( Briumvi – TG Therapeutics) for IV treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Two other anti-CD20 antibodies, IV ocrelizumab (Ocrevus) and SC ofatumumab (Kesimpta) , are also FDA-approved for these indications.
Issue 1630 · August 9, 2021
Ponesimod (Ponvory) for Multiple Sclerosis

The FDA has approved ponesimod ( Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated…

Med Lett Drugs Ther. 2021 Aug 9; 63(1630):123-5
The FDA has approved ponesimod ( Ponvory – Janssen), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Ponesimod is the fourth oral S1P receptor modulator to be approved in the US for once-daily treatment of relapsing forms of MS; ozanimod (Zeposia) and siponimod (Mayzent) are also approved for use in adults, and fingolimod (Gilenya) is indicated for use in patients ≥10 years old.
Issue 1620 · March 22, 2021
Drugs for Multiple Sclerosis

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations,…

Med Lett Drugs Ther. 2021 Mar 22; 63(1620):42-8
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Issue 1605 · August 24, 2020
Ozanimod (Zeposia) for Multiple Sclerosis

The FDA has approved ozanimod ( Zeposia – Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated…

Med Lett Drugs Ther. 2020 Aug 24; 62(1605):132-4
The FDA has approved ozanimod ( Zeposia – Celgene), a sphingosine 1-phosphate (S1P) receptor modulator, for treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). It is the third oral S1P receptor modulator to be approved in the US for treatment of relapsing forms of MS; siponimod (Mayzent) is also indicated for use in adults, and fingolimod (Gilenya) is approved for use in patients ≥10 years old.
Issue 1577 · July 29, 2019
Cladribine (Mavenclad) for Multiple Sclerosis

The FDA has approved cladribine ( Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and…

Med Lett Drugs Ther. 2019 Jul 29; 61(1577):118-20
The FDA has approved cladribine ( Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive MS (SPMS), who cannot tolerate or have had an inadequate response to other drugs indicated for treatment of MS. It is not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved for treatment of hairy cell leukemia, has been used off-label for treatment of MS.
Issue 1523 · June 19, 2017
Ocrelizumab (Ocrevus) for MS

The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first…

Med Lett Drugs Ther. 2017 Jun 19; 59(1523):98-101
The FDA has approved ocrelizumab ( Ocrevus – Genentech), a humanized anti-CD20 monoclonal antibody, for treatment of adults with primary progressive or relapsing multiple sclerosis (MS). It is the first anti-CD20 monoclonal antibody to be approved for treatment of MS and the first disease-modifying drug to be approved in the US for primary progressive MS.
Issue 1503 · September 12, 2016
Daclizumab (Zinbryta) for Multiple Sclerosis

The FDA has approved daclizumab ( Zinbryta – Biogen/Abbvie), an interleukin-2 (IL-2) receptor blocking monoclonal antibody, for treatment of adults with relapsing forms of multiple sclerosis (MS). It is the…

Med Lett Drugs Ther. 2016 Sep 12; 58(1503):117-9
The FDA has approved daclizumab ( Zinbryta – Biogen/Abbvie), an interleukin-2 (IL-2) receptor blocking monoclonal antibody, for treatment of adults with relapsing forms of multiple sclerosis (MS). It is the first subcutaneously injected monoclonal antibody to be approved for treatment of MS.
Issue 1496 · June 6, 2016
Drugs for Multiple Sclerosis

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as…

Med Lett Drugs Ther. 2016 Jun 6; 58(1496):71-4
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as fatigue, depression, and pain, and corticosteroids for acute exacerbations.
Issue 1468 · May 11, 2015
Peginterferon Beta-1a (Plegridy) for Multiple Sclerosis

The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).

Med Lett Drugs Ther. 2015 May 11; 57(1468):67-9
The FDA has approved a pegylated form of interferon beta-1a ( Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).
Issue 1418 · June 10, 2013
Dimethyl Fumarate (Tecfidera) for Multiple Sclerosis

The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years…

Med Lett Drugs Ther. 2013 Jun 10; 55(1418):45-7
The FDA has approved dimethyl fumarate ( Tecfidera – Biogen Idec), formerly called BG-12, for treatment of relapsing forms of multiple sclerosis (MS). It is the third oral drug to be approved in recent years for this indication.
Issue 1403 · November 12, 2012
New Drugs for Multiple Sclerosis

In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS), and many others are in the pipeline. Most recently, teriflunomide ( Aubagio – Genzyme) became the second…

Med Lett Drugs Ther. 2012 Nov 12; 54(1403):89-91
In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS), and many others are in the pipeline. Most recently, teriflunomide ( Aubagio – Genzyme) became the second oral drug to be approved by the FDA for treatment of relapsing forms of MS.
Issue 1353 · December 13, 2010
Oral Fingolimod (Gilenya) for Multiple Sclerosis

The FDA has approved the marketing of fingolimod ( Gilenya – Novartis) to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with relapsing forms of…

Med Lett Drugs Ther. 2010 Dec 13; 52(1353):98-100
The FDA has approved the marketing of fingolimod ( Gilenya – Novartis) to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability in patients with relapsing forms of multiple sclerosis (MS). Fingolimod is the first oral drug approved for this indication.
Issue 1350 · November 1, 2010
Interferon Beta-1b (Extavia) for Multiple Sclerosis

The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the…

Med Lett Drugs Ther. 2010 Nov 1; 52(1350):86-7
The FDA has approved a new interferon beta-1b product ( Extavia – Novartis) for treatment of relapsing forms of multiple sclerosis (MS). Extavia is identical to Betaseron (Bayer); both are produced in the same factory and packaged separately.
Issue 1347 · September 20, 2010
Dalfampridine (Ampyra) for MS

The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered a…

Med Lett Drugs Ther. 2010 Sep 20; 52(1347):73-4
The FDA has approved the use of dalfampridine (4-aminopyridine; Ampyra – Acorda), a potassium channel blocker, to improve walking speed in patients with multiple sclerosis (MS). Walking speed is considered a reliable clinical measure of impairment in patients with MS.
Issue 1307 · March 9, 2009
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis

Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ…

Med Lett Drugs Ther. 2009 Mar 9; 51(1307):17-8
Alemtuzumab (Campath) , a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried off-label for treatment of relapsing multiple sclerosis (MS).
Issue 1202 · February 14, 2005
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis

Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and…

Med Lett Drugs Ther. 2005 Feb 14; 47(1202):13-5
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.
Issue 1004 · July 4, 1997
Glatiramer Acetate for Relapsing Multiple Sclerosis

Glatiramer acetate ( Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis…

Med Lett Drugs Ther. 1997 Jul 4; 39(1004):61-2
Glatiramer acetate ( Copaxone - Teva Marion Partners), formerly known as copolymer-l, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (MS). Interferon β-1b ( Betaseron ) and interferon β-1a ( Avonex - Medical Letter, 38:63, 1996) were previously approved for this indication.